NCT03603145 (INTRAM) is a Phase 3 clinical trial of Immediate insertion in Contraceptive Usage, sponsored by Karolinska Institutet.

Who is sponsoring NCT03603145?

NCT03603145 is sponsored by Karolinska Institutet.

What drugs are being tested in NCT03603145?

Interventions in NCT03603145: Immediate insertion.

What condition does NCT03603145 study?

NCT03603145 studies Contraceptive Usage.

Is NCT03603145 still recruiting?

NCT03603145 is currently status unknown. Last updated 1 May 2023.

Last reviewed 2023-05-01 · How we verify

NCT03603145: INTRAM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immediate Versus Delayed Insertion of Intrauterine Contraception After Medical Abortion

Status unknown Phase 3 Last updated 1 May 2023

What this trial tests

Phase 3 trial testing Immediate insertion in Contraceptive Usage in 720 participants. Status unknown.

Timeline

16 January 2019

Primary endpoint
31 December 2023

31 December 2024

Quick facts

Lead sponsor	Karolinska Institutet
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	720
Start date	16 January 2019
Primary completion	31 December 2023
Estimated completion	31 December 2024
Sites	6 locations across Sweden

Drugs / interventions tested

Immediate insertion

Conditions studied

Contraceptive Usage — all drugs for Contraceptive Usage →

Sponsor

Karolinska Institutet

Who can join

18 and older, female only, with Contraceptive Usage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PICO: Population: Women with unwanted pregnancy having a medical abortion and fulfilling inclusion and without exclusion criteria and opting for IUC as post abortion contraception. The medical abortion will be carried out according to the Swedish national evidence based guidelines. Intervention: Randomized to insertion of IUC within 48 hours after medical abortion. Control: Randomized to insertion of IUC at the time of a follow-up visit scheduled 2 to 4 weeks after the abortion according to routine care. Objectives: Evaluation of use of IUC, feasibility, safety, compliance, and acceptability of immediate insertion of IUC 0 to 48 hours after medical abortion compared with delayed IUC insertion at 2 to 4 weeks post abortion. The primary outcome measure will be the use of IUC at 6 months in both groups evaluated by telephone calls/emails follow up. Time plan: Planning: -March 2018 Study start: May 2018 End of recruitment: April 2020 Last patient Last visit April 2021 Analysis: 2021 Report of primary outcome and Safety: 2021

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

One-year follow up of contraceptive use and pregnancy rates after early medical abortion: Secondary outcomes from a randomized controlled trial of immediate post-abortion placement of intrauterine devices.
Hogmark S, Envall N, Gemzell-Danielsson K, Kopp Kallner H. · · 2023 · cited 2× · PMID 37614066 · DOI 10.1111/aogs.14662
Immediate and delayed placement of the intrauterine device after abortion: a systematic review and meta-analysis.
Lou Y, Tang S, Sheng Z, Lian H, et al · · 2024 · PMID 38762680 · DOI 10.1038/s41598-024-62327-1

Verify or expand the search:

Other recruiting trials for Contraceptive Usage

Currently open trials in the same condition.

NCT07039591 — Assess Performance Attributes and Acceptability of Non-medicated Intravaginal Rings Among Sexually Active Women in Atlan · EARLY_PHASE1 · recruiting
NCT06682065 — Telemedicine Contraceptive Counselling (TECC) Versus Standard Care · NA · recruiting
NCT05674513 — Disparities in Emergency Contraceptive Metabolism Dictate Efficacy · Phase 4 · recruiting
NCT04558229 — RCT Evaluating Standardized Counseling on Early Discontinuation for Irregular Bleeding in Nexplanon Users · Phase 4 · active not recruiting
NCT03984695 — Sexual Health Empowerment for Women's Health · NA · active not recruiting

Other Karolinska Institutet trials

Trials by the same sponsor.

NCT06359262 — Evaluating the Hope@School Prevention Program · NA · not yet recruiting
NCT07289490 — Bilateral vs Unilateral Inguinal Hernia Repairs With an Asymptomatic Inguinal Hernia in Bilateral Hernias · NA · not yet recruiting
NCT06894264 — Emotion Processing and Regulation in People With Intellectual Disability · NA · not yet recruiting
NCT07494266 — Safety of a Healthy Plant-based Diet With Higher Potassium Content, Compared to a Healthy Plant-based Diet With Limited · NA · not yet recruiting
NCT07442032 — Cardiovascular Phenotypes in Sepsis · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03603145 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Karolinska Institutet
Last refreshed: 1 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03603145.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing